Overview
MR (Magnetic Resonance Imaging) - based IGRT (image-guided radiotherapy) for patients with prostate carcinoma.
Description
Single arm, phase II study, MR (Magnetic Resonance Imaging) - based IGRT (Image-guided radiotherapy) of prostate cancer.
Primary endpoint: Grade 2+ GI (gastrointestinal) and genitourinary (GU) toxicity after 2 years.
Eligibility
Inclusion Criteria:
- histologically proven prostate cancer
- indication for curative treatment
- ECOG performance scale 0-2
- Informed consent
Exclusion Criteria:
- contraindications for curative treatment
- age<18year
- previous pelvic radiotherapy or prostatic treatment like TURP (transurethral resection of prostate), HIFU (high intensity focused ultrasound)
- serious comorbidity leading to inability for IGRT (image-guided radiotherapy)
- contraindications for MRI (Magnetic Resonance Imaging)